Abstract
To assess the impact on the hospitalization rate due to RSV and financial impact of Palivizumab’s use in neonates or children up to 2 years of age with comorbidities who are eligible for the treatment.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
